HomeAI · summaries
Storia in 8 fonti
Generic drugmakers gain key victory in ‘skinny label’ patent case
The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
washingtonexaminer.com
Treatment for millions at stake in 'skinny label' Supreme Court case
The Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. ruling could have a major effect on incentives to invest in research for FDA‑approved medicines.
- ·
medpagetoday.com
Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case
Court says defendant Amarin Pharma hasn't shown enough harm; remands case to lower court
